CAR-T therapy, a new category of cellular immunotherapy, is rapidly shifting the care paradigm by harnessing the immune system to fight cancer. We discuss the therapy spectrum, current CAR-T adoption, and financial feasibility.
As the technology proliferates, it will be imperative that academic and large community cancer centers understand the treatment and its specific applications in their local environment and create plans for CAR-T program implementation. In coming years, we believe immune cell therapy will migrate from a program differentiator to a requirement for provision of contemporary cancer care.
